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IMPORTANCE Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in
addition to trastuzumab and lapatinib, are needed.
OBJECTIVE Todeterminewhether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor,
plus paclitaxel improves progression-free survival comparedwith trastuzumabplus paclitaxel in
the first-line treatment of recurrent and/ormetastatic ERBB2-positive breast cancer.
DESIGN, SETTING, AND PARTICIPANTS In the randomized, controlled, open-label NEfERT-T trial
conducted from August 2009 to December 2014 at 188 centers in 34 countries in Europe,
Asia, Africa, and North America, 479 womenwith previously untreated recurrent and/or
metastatic ERBB2-positive breast cancer were randomized to 1 of 2 treatment arms
(neratinib-paclitaxel [n = 242] or trastuzumab-paclitaxel [n = 237]). Womenwith
asymptomatic central nervous systemmetastases were eligible, and randomization was
stratified by prior trastuzumab and lapatinib exposure, hormone-receptor status, and region.
INTERVENTIONS Women received neratinib (240mg/d orally) or trastuzumab (4mg/kg then
2mg/kg weekly), each combined with paclitaxel (80mg/m2 on days 1, 8, and 15 every 28
days). Primary prophylaxis for diarrhea was not mandatory.
MAINOUTCOMEANDMEASURES Theprimary outcomewasprogression-free survival.
Secondary endpointswere response rate, clinical benefit rate, duration of response, frequency,
and time to symptomatic and/or progressive central nervous system lesions, and safety.
RESULTS The intent-to-treat population comprised 479women 18 years or older
(neratinib-paclitaxel, n = 242; trastuzumab-paclitaxel, n = 237) randomized and stratified in
their respective treatment arms by prior trastuzumab and lapatinib exposure,
hormone-receptor status, and region. Median progression-free survival was 12.9months
(95% CI, 11.1-14.9) with neratinib-paclitaxel and 12.9months (95% CI, 11.1-14.8) with
trastuzumab-paclitaxel (hazard ratio [HR], 1.02; 95% CI, 0.81-1.27; P =.89). With
neratinib-paclitaxel, the incidence of central nervous system recurrences was lower (relative
risk, 0.48; 95% CI, 0.29-0.79; P = .002) and time to central nervous systemmetastases
delayed (HR, 0.45; 95% CI, 0.26-0.78; P = .004). Common grade 3 to 4 adverse events were
diarrhea (73 of 240 patients [30.4%] with neratinib-paclitaxel and 9 of 234 patients [3.8%]
with trastuzumab-paclitaxel), neutropenia (31 patients [12.9%] vs 34 patients [14.5%]) and
leukopenia (19 patients [7.9%] vs 25 patients [10.7%]); no grade 4 diarrhea was observed.
CONCLUSIONS AND RELEVANCE In first-line ERBB2-positivemetastatic breast cancer,
neratinib-paclitaxel was not superior to trastuzumab-paclitaxel in terms of progression-free
survival. In spite of similar overall efficacy, neratinib-paclitaxel may delay the onset and
reduce the frequency of central nervous system progression, a finding that requires a larger
study to confirm.
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O ver the past 15 years, therapies directed againsthuman epidermal growth factor receptor 2 (ERBB2[formerly HER2 or HER2/neu]) have improved over-
all survival in patients with early-stage1,2 and metastatic
ERBB2-positive breast cancers.3,4 However, patients with
stage IV disease still die on average 2 to 5 years after
relapse.4-6 Metastatic ERBB2-positive breast cancer has a
characteristic pattern of spread, with over 75% of patients de-
veloping livermetastases,7 andapproximatelyhalfwithpoor–
prognosis central nervous system (CNS) involvement.8 Re-
cent studies suggest that small-molecule ERBB2 kinase
inhibitors may be effective in patients with ERBB2-positive
metastatic breast cancer and CNSmetastases.9,10
Neratinib (Puma Biotechnology Inc) is an oral small-
molecule tyrosine kinase inhibitor of ERBB1, ERBB2, and
ERBB411 that binds irreversibly to the intracellular domain of
ERBB receptors, leading to sustained inhibition of signal
transduction.12Neratinibhasdemonstrated clinical activity in
patientswithERBB2-positivemetastatic breast cancer both as
a single agent13 and in combinationwith various chemothera-
peutic agents, includingpaclitaxel.14Diarrhea is themost com-
mon toxic effect associated with neratinib13 and is nowman-
aged with intensive primary antidiarrheal prophylaxis
administered with the first cycle of neratinib.15,16
Study 3144A2-3005-WW (NEfERT-T) evaluated the
efficacy and safety of first-line neratinib plus paclitaxel
comparedwith trastuzumabpluspaclitaxel inwomenwith lo-
cally recurrent ormetastatic ERBB2-positivebreast cancer, in-
cluding thosewith asymptomatic CNSmetastases.We report
here the efficacy and safety analyses from this phase 2 ran-
domized study.
Methods
Study Design
NEfERT-T was initiated in 2009 as a multinational, open-
label, randomizedphase3 trial todeterminewhetherneratinib-
paclitaxelwas superior to trastuzumab-paclitaxel as first-line
treatment for women with metastatic ERBB2-positive breast
cancer (Trial Protocol is available in Supplement 1). In June
2011, the study goals and statistical parameters were revised
afterneratinibwaspassed fromWyeth toPfizer andafter it be-
came evident that the estimate of progression-free survival
(PFS)usedtodeterminethesamplesize (controlarm,9months)
was shorter than in the CHAT17 and HERNATA18 studies (ap-
proximately 12months)whichwere reported at that time.The
studyobjectivewas revised to gain apreliminaryunderstand-
ingof the safety andefficacyofneratinib-paclitaxel in the con-
textof a randomizedstudy.Theaccrual goalwas reduced from
1200 to480patients, and subsequently the studywasno lon-
ger poweredas a randomizedphase 3 study. This decisionwas
not related to any safety issue and was made without any
knowledge of the efficacy data.
Approval of the protocol was obtained at participating
sites from an institutional review board and/or independent
ethics committee. All patients provided written informed
consent.
Study Population
Women 18 years and older with measurable histologically
and/or cytologically confirmed inoperable locally recurrent or
metastatic breast cancer were eligible. Documentation of
ERBB2-amplification (fluorescence insituhybridization [FISH]
score>2.2or chromogenic in situhybridization [CISH] accord-
ing to manufacturer instructions) or ERBB2-overexpression
(immunohistochemistry score 3+or2+withFISHorCISHcon-
firmation) at a local or central laboratory was required. Prior
systemic therapy formetastatic disease, excluding endocrine
therapy, andprior treatmentwith anERBB2 inhibitor, exclud-
ing trastuzumab and/or lapatinib in the (neo)adjuvant set-
ting, was not allowed. Women with newly detected asymp-
tomaticCNSmetastases, ahistoryofCNSmetastases, or spinal
involvementwithcordcompressionwereeligibleprovidedthat
they were asymptomatic, had been treated definitively with
surgery and/or radiation therapy, and had not received anti-
convulsants or steroids within 4 weeks prior to study treat-
ment. Patients had adequate organ and hematological func-
tion.
Randomization andMasking
A centralized permuted block randomization procedure
through an interactive voice response systemwas used to as-
sign patients to each treatment group (1:1 ratio). Randomiza-
tionwasstratifiedbyprior trastuzumabexposure (yes/no),prior
lapatinib exposure (yes/no), estrogen receptor (ER)/
progesterone receptor (PgR) status (ER-positive and/or PgR-
positive/ER-negative and PgR-negative), and region. Neither
participants nor investigators were masked to treatment
allocation.
Treatment
Eligiblepatientswere randomlyassigned(1:1) to treatmentwith
either neratinib (240mg orally once daily) plus paclitaxel (80
mg/m2 intravenously on days 1, 8, and 15 every 28 days) or
trastuzumab(4mg/kg loadingdose intravenously then2mg/kg
ondays 1,8, 15, and22every28days)pluspaclitaxel (80mg/m2
intravenously on days 1, 8, and 15 every 28 days). Treatment
was initiated within 2 days of randomization and continued
Key Points
Question Does neratinib plus paclitaxel improve progression-free
survival compared with trastuzumab plus paclitaxel as first-line
therapy in recurrent and/or metastatic ERBB2-positive breast
cancer?
Findings In this randomized clinical trial that included 479
women, median progression-free survival was 12.9months with
neratinib-paclitaxel and 12.9months with trastuzumab-paclitaxel
with no statistically significant difference between groups. The
incidence of central nervous system (CNS) recurrences was
significantly lower and time to CNSmetastases significantly
delayed with neratinib-paclitaxel.
Meaning Neratinib-paclitaxel is not superior to trastuzumab-
paclitaxel in terms of progression-free survival in previously
untreated womenwith ERBB2-positive metastatic breast cancer,
and the CNS findings warrant further clinical investigation.
Research Original Investigation The NEfERT-T Randomized Clinical Trial
1558 JAMAOncology December 2016 Volume 2, Number 12 (Reprinted) jamaoncology.com
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
until disease progression, symptomatic deterioration, unac-
ceptable toxic effects, death, or withdrawal of consent. Nera-
tinib compliance was monitored using tablet counts and drug
inventory records. Toxic effect–related dose reductions for
neratinib (first dose reduction: 160 mg/d; second: 120 mg/d)
and paclitaxel (first dose reduction: 70 mg/m2; second: 60
mg/m2) were permitted. Patients discontinued neratinib
and/or paclitaxel if more than 2 dose reductions were
required or if treatment was delayed more than 3 weeks. Pri-
mary prophylaxis and management for diarrhea with low-
dose loperamide (2 mg with each neratinib dose) was recom-
mended but not mandatory.
Assessments
Atbaseline, informationregardingdemography (including race
[Asian, black/AfricanAmerican,white, other] classifiedby the
investigator) andcancerhistorywere collected.Tumorassess-
ments (contrast-enhancedcomputedtomography[CT]ormag-
netic resonance imaging[MRI]of thechest,abdomen,andliver)
were performed at baseline and every 8weeks thereafter un-
til objective disease progression. For patients without docu-
mented objective disease progression at treatment discon-
tinuation, scans continued every 8 weeks until objective
disease progression, initiation of new anticancer treatment,
or death. Additional imaging (ie, bone scans, contrast-
enhanced CT or MRI of the brain or other sites) was per-
formed at baseline and repeated every 8weeks if diseasewas
present and/or if clinically indicated. InMarch 2012, after en-
rolment was complete, the frequency of tumor assessments
was changed to every 12weeks to alleviatepatient burdenand
be in line with clinical practice. Adverse events were graded
according toNational Cancer Institute CommonTerminology
Criteria for Adverse Events, version 3.0. Patient-reported
health-related quality of life (QoL) was assessed with Func-
tional Assessment of Cancer Therapy–Breast (FACT-B), ver-
sion 4, and EuroQol 5-Dimensions visual analogue scale (EQ-
5D-VAS) completed at baseline, cycle 2, and every 2 cycles
thereafteruntil treatmentdiscontinuation.Health-relatedQoL
data were not collected after June 2011.
Outcomes
The primary end point was PFS. Secondary end points were
objective response rate, duration of response, clinical benefit
rate, frequencyof and time to symptomaticorprogressiveCNS
lesions, andsafety.Health-relatedQoLwasanexploratoryend-
point. All tumor-based efficacy end points were assessed by
investigators and are defined in eTable 1 in Supplement 2.
Statistical Analysis
The studywas to enroll 480patients todetect a 30% improve-
ment inmedianPFS (basedonassumptions in theoriginalpro-
tocol that themedian PFSwould be 11.7months in the experi-
mental armofneratinib-paclitaxel and9months in the control
arm of trastuzumab-paclitaxel) with 80% power at a 1-sided
significance level of .075. The studywas event driven; a total
of 304 PFS events were needed. No interim analysis was
planned. As the requisite number of PFS eventswere reached
for the primary analysis in accordance with the protocol, the
trial ended as planned, and this report describes the first and
final analysis from this study. The cut-off date for this analy-
sis was December 16, 2014.
Efficacy analyseswere basedon the intent-to-treat popu-
lation (ie, all randomizedpatients). Time-to-event endpoints
were analyzed using a Cox proportional hazards regression
model stratified for randomization factors and presented as
hazard ratioswith 95% confidence intervals (CI). Median val-
ueswereestimatedusing theKaplan-Meiermethod, and treat-
ment groupswere comparedusinga log-rank test stratified for
randomization factors. Response rates and frequency of CNS
lesionswerecomparedusing theCochranMantel-Haenszel test
adjusted for randomization factors.Cumulative incidencewith
competing risksanalysiswasperformedforCNS lesions,where
progression events occurring at extracranial sites and deaths
were considered competing risks; the Gray test was used to
compare treatments.19 Prespecified subgroup analyses were
performed to examine whether treatment effect on PFS var-
ied across prognostic factors. Adverse events were summa-
rized by treatment arm for the safety population (ie, all pa-
tients who received ≥1 dose of study treatment). Changes in
health-related QoL scores from baseline were analyzed using
a linear mixed-model for repeated measures with baseline
score, treatment, cyclesand interactionof treatmentandcycles
as covariates.Nomultiplicity adjustmentswere applied in the
statistical tests. AllPvalues arenominal at a significance level
of .05.All analyseswereperformedusingSASEnterpriseGuide
5.1 (SAS Institute Inc).
Results
Between August 21, 2009, and August 21, 2011, 479 patients
were enrolled from 188 centers and randomly assigned to ne-
ratinib-paclitaxel (n = 242)or trastuzumab-paclitaxel (n = 237)
(Figure 1). Treatment groups were well balanced in terms of
baseline characteristics (eTable 2 in Supplement 2). The me-
dian (interquartile range [IQR]) follow-upof the studywas23.0
(13.8-32.3) months.
Efficacy
Overall, 167patients (69.0%) in theneratinib-paclitaxel group
had PFS events compared with 156 patients (65.8%) in the
trastuzumab-paclitaxel group (Table). Median PFS was 12.9
(95%CI, 11.1-14.9)months in theneratinib-paclitaxel groupand
12.9 (95% CI, 11.1-14.8) months in the trastuzumab-paclitaxel
group (hazard ratio [HR], 1.02; 95% CI, 0.81-1.27; P = .89)
(Figure 2A). Subgroup analyses of PFS showed similar out-
comes in all patient subgroups (ie, age, race, region, hormone
receptor status, prior trastuzumab exposure), although there
was some heterogeneity around the HR point estimates for
smaller subgroups (eFigure 1 in Supplement 2). Kaplan-Meier
curvesof PFSaccording tohormone receptor status are shown
in eFigure 2 in Supplement 2.
At the cut-off date, 78 patients (32.2%) in the neratinib-
paclitaxel group had died comparedwith 72 patients (30.4%)
in the trastuzumab-paclitaxel group (HR, 1.05; 95% CI, 0.76-
1.45; P = .77) (Figure 2B).
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Theobjective response ratewas74.8%(181patients) in the
neratinib-paclitaxel group and 77.6% (184 patients) in the
trastuzumab-paclitaxel group (P = .52), and the clinical ben-
efit rateswere 88.4% (214 patients) and 85.2% (202 patients),
respectively (P = .24). The median duration of response was
also similar inbothgroups (HR, 1.01; 95%CI,0.78-1.32;P = .92)
(Table).
The median (IQR) duration of treatment was 44.6 (23.4-
72.0) weeks in the neratinib-paclitaxel group and 44.1 (25.3-
72.1) weeks in the trastuzumab-paclitaxel group (eTable 3 in
Supplement 2). The most common reason for discontinuing
study treatmentwasdiseaseprogression (neratinib-paclitaxel,
n = 157; trastuzumab-paclitaxel, n = 149). Mean relative dose
intensity exceeded 90% for all agents.
Symptomatic or progressive CNS recurrences occurred in
20patients (8.3%) in theneratinib-paclitaxel groupand41pa-
tients (17.3%) in the trastuzumab-paclitaxelgroup (relative risk,
0.48; 95%CI, 0.29-0.79; P = .002) (Table); in 50 patients this
wasan isolatedCNSevent.TheestimatedKaplan-Meier 2-year
incidence of CNS recurrences was 16.3% in the neratinib-
paclitaxelgroupand31.2%in the trastuzumab-paclitaxelgroup
(HR, 0.45; 95% CI, 0.26-0.78; P = .004). Based on the com-
peting risks model, the 2-year estimated cumulative inci-
dence was 10.1% in the neratinib-paclitaxel group and 20.2%
in the trastuzumab-paclitaxel group (P = .002) (Figure2C).Ne-
ratinib treatmenteffectonbothCNSendpoints appearedsimi-
lar in those with and without baseline CNS disease and re-
mainedstatisticallysignificantafteradjusting for the imbalance
ofbaselineCNSmetastases (CochranMantel-HaenszelP = .02;
Cox model HR 0.56; P = .045).
Safety
Themost common treatment-emergent adverse events in the
neratinib-paclitaxel groupwerediarrhea (92.5%vs33.3%with
trastuzumab-paclitaxel), alopecia (52.1% vs 56.4%), and nau-
sea (44.2% vs 30.3%) (eTable 4 in Supplement 2). The most
common grade 3 events were diarrhea (30.4%, neratinib-
paclitaxel vs 3.8%, trastuzumab-paclitaxel;P < .001), neutro-
penia (11.3% vs 12.4%, respectively), and leukopenia (6.7% vs
10.3%, respectively). Grade 4 events occurred in 5.8% of pa-
tients in the neratinib-paclitaxel group and 4.7% of patients
in the trastuzumab-paclitaxel group. Grade 4 febrile neutro-
penia occurred in 1 (0.4%) neratinib-paclitaxel–treated pa-
tient, and no grade 4 diarrhea was observed. Peripheral neu-
ropathy and fatigue occurred at similar rates in both groups
(eTable 4 in Supplement 2). Grade 3 or higher cardiac events
(ie, cardiac failure, decreased ejection fraction, left ventricu-
lar dysfunctionand [peripheral] edema)were reported in3pa-
tients (1.3%) in the neratinib-paclitaxel group and 7 patients
(3.0%) in the trastuzumab-paclitaxel group.
The incidence of grade 3 diarrhea in the neratinib-
paclitaxel group was highest in the first month of treatment;
most events thereafter were grade 1 or 2 (eFigure 3 in
Supplement 2). Median (IQR) time to onset of grade 3 diar-
rheawas 16 (6-65) days,with amedian (IQR)durationof 2 (1-3)
days per event and 5 (3-9) days per patient (eTable 5 in
Supplement 2). Diarrhea led todiscontinuationof study treat-
ment in 9 neratinib-paclitaxel–treated patients (3.8%) and 1
trastuzumab-paclitaxel–treated patient (0.4%).
Three patients in the neratinib-paclitaxel group died as a
result of treatment-relatedadverse events (septic shock, n = 1;
intestinal obstruction, shock, n = 1; ascites, n = 1), as did 1 pa-
tient in the trastuzumab-paclitaxel group (pneumonitis).
Patient-Reported Health-Related QoL
Mean scores by treatment over time showed similar patterns
for FACT-B and EQ-5D-VAS (eFigures 4 and 5 in Supplement
2).While early treatmentdifferences appeared to favor trastu-
zumab-paclitaxel, none exceeded the differences considered
to be clinically meaningful for either instrument.20,21 Later
treatment differences appeared to favor neratinib-
paclitaxel, but sample sizes were small. Treatment-by-time
interaction was significant in the mixed-effect model for
FACT-B (P = .02) but not for EQ-5D-VAS (P = .13) (eFigures 4
and 5 in Supplement 2).
Discussion
This randomizedcontrolled studydidnotdemonstrate the su-
periorityofneratinib-paclitaxel in termsofPFScomparedwith
trastuzumab-paclitaxel as first-line therapy in women with
ERBB2-positive metastatic breast cancer. Also, no statisti-
cally significantdifferenceswereobservedbetweenthe2 treat-
ment groups for 3 of 5 secondary efficacy end points (ie,
Figure 1. NEfERT-T Patient Flowchart
774 Screened
295 Failed screening
271 Did not meet inclusion
criteria a
1 Lost to follow-up
12 Other reasons
10 Subject request
1 Death
479 Randomized
479 Eligible
242 Randomized to receive
neratinib + paclitaxel
240 Received study treatment
as randomized
2 Did not receive study
treatment as randomized
27 Remain on study
75 Death
215 Ended study
92 Discontinuation of study b
10 Lost to follow-up
38 Patient request
237 Randomized to receive
trastuzumab + paclitaxel
234 Received study treatment
as randomized
3 Did not receive study
treatment as randomized
30 Remain on study
207 Ended study
70 Death
105 Discontinuation of study b
5 Lost to follow-up
27 Patient request
a Patients referred for ERBB2 testing but the testing was not performed.
b Long-term follow-up for overall survival was removed from the study protocol
March 2012 (amendment 6). Patients who ended study for this reason were
recorded as “discontinuation of study by sponsor.”
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objective response rate, clinicalbenefit rate, anddurationof re-
sponse), which suggests that the 2 regimens have similar effi-
cacy in this patient population. This was further supported by
a prespecified subgroup analysis of PFS that showed consis-
tentoutcomesacrossmost subgroupsand theanalysis of over-
all survival that showed similar outcomes in both treatment
groups. The control group in the NEfERT-T trial performed as
expected,withamedianPFSof 12.9monthscomparedwith 11.1
to 14.6 months reported with trastuzumab-taxane combina-
tions in other first-line randomized controlled studies,6,17,22-26
reinforcing the validity of the present study.
Central nervous system events are a challenging problem
in ERBB2-positive breast cancer, as demonstrated by the fo-
cus on this end point in multiple studies of novel ERBB2-
targeting approaches inmetastatic breast cancer.27-30 Phase 2
studies suggest modest activity of lapatinib-based combina-
tions uponCNS endpoints9,10 as predicted by preclinical data
reporting some CNS penetration.31-33 However, a prospective
randomized trial, CEREBEL,27 found no difference between
lapatinib-capecitabineand trastuzumab-capecitabinewith re-
spect to CNS end points in patients with metastatic ERBB2-
positive disease without CNS involvement at entry, although
the rates of CNS progression were very low (3%-5%). In the
NEfERT-T trial, CNS recurrence and timingwere prospectively
defined secondary efficacy end points, and we observed a re-
duction in the frequencyof symptomaticorprogressiveCNSre-
currences, aswell as an improvement in the time to the occur-
renceof theseevents intheneratinib-paclitaxelgroupcompared
with the trastuzumab-paclitaxel group.Between-groupdiffer-
ences remainedafter adjusting for imbalances inCNSmetasta-
ses at baseline.As the studyprotocol didnot include screening
forCNSmetastasesbut rather identifiedCNSmetastasesonpre-
sentationof symptoms, it is likely thatCNSeventswereunder-
estimated in this study.We acknowledge that therewas an im-
balancebetweenstudyarmswithtwiceasmanypatientshaving
prior CNS disease at baseline in the control comparedwith the
experimental arm and, therefore, a possible inherent bias to-
ward imaging the brain in these patients that might have re-
sulted inmore frequentdetectionofCNSmetastases in thecon-
trol arm. We suggest that CNS outcomes with neratinib are
worthyof further investigation ina largephase3 trialwhich in-
cludes predefined CNS end points.
Diarrheaandgastrointestinal toxiceffects (ie,nausea,vom-
iting)were themain adverse events associatedwithneratinib-
paclitaxel and consistent with the safety profile previously
documented for this combination,14 although primary pro-
phylaxis for diarrhea was not mandatory in NEfERT-T. Re-
cent trials with neratinib show that diarrhea can bemanaged
with intensive primary antidiarrheal prophylaxis adminis-
teredwith the first cycle of neratinib therapy.15,16 Despite the
lack of effective preventivemeasures in NEfERT-T, treatment
exposurewas similar inboth treatmentgroups, overall health-
related QoLwasmaintained, 12 of 240 patients (5%) required
hospital admission because of diarrhea, and no grade 4 diar-
rhea was observed. Other common toxic effects observed in
NEfERT-T were those typically associated with paclitaxel (ie,
hematological events, peripheral neuropathy) that occurred
at similar rates in both treatment groups.
The current landscape of treatment for ERBB2-positive
breast cancer includesdemonstration in the randomizedphase
3 setting of survival benefits for pertuzumab-trastuzumab-
paclitaxel comparedwith trastuzumab-paclitaxel alone in the
first-linemetastatic setting,4,23 and ado-trastuzumab emtan-
sineover lapatinib-capecitabine in thepretreated setting34but
Table. Efficacy Analyses in the Intent-to-Treat Populationa
Variable
Neratinib Plus
Paclitaxel
(n = 242)
Trastuzumab Plus
Paclitaxel
(n = 237)
Hazard Ratio or
Difference (95% CI) P Value
Primary end points
Patients with PFS event,
No. (%)
167 (69.0) 156 (65.8) 1.02 (0.81 to 1.27) .89b
Median PFS, mo 12.9 12.9 … …
95% CI 11.1-14.9 11.1-14.8 … …
Secondary end points
Objective response rate,
No. (%)c
181 (74.8) 184 (77.6) –2.8 (–10.5 to 4.8)d .52c
95% CI 68.8-80.1 71.8-82.8 … …
Complete responsee 4 (1.7) 9 (3.8) … …
Partial responsee 177 (73.1) 175 (73.8) … …
Clinical benefit rate,
No. (%)
214 (88.4) 202 (85.2) 3.2 (–2.9 to 9.3)d .24c
95% CI 83.7-92.2 80.1-89.5
Median duration of
response, mof
13.4 12.9 1.01 (0.78 to 1.32) .92b
95% CI 11.4-16.8 11.0-15.9 … …
Incidence of symptomatic
or progressive CNS events,
No. (%)
20 (8.3) 41 (17.3) 0.48 (0.29 to 0.79)g .002c
First quartile, 25%, time to
CNS events, mo,
(95% CI)
Not reached 18.3 (12.3-41.3) … …
Abbreviations: CI, confidence
interval; CNS, central nervous
system; PFS, progression-free
survival; ellipses, data not applicable.
a All end points by investigator
assessment.
b Stratified log-rank test.
c Adjusted CochranMantel-Haenszel
test.
dDifference.
e Confirmed responses.
f Assessed in 181 and 184 patients in
the neratinib-paclitaxel and
trastuzumab-paclitaxel groups,
respectively.
g Relative risk.
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not in the first-line setting.35 In the neoadjuvant and adju-
vant settings, lapatinib-paclitaxel is less effective than
trastuzumab-paclitaxel.36-38 The NEfERT-T study, which
demonstrates similar efficacy of neratinib-paclitaxel to
trastuzumab-paclitaxel in the first-line metastatic setting,
suggests that neratinib is nomore effective than trastuzumab
Figure 2. Estimates for Progression-Free Survival, Overall Survival, and Cumulative Incidence of Symptomatic
or Progressive Central Nervous System (CNS) Lesions
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in unselected ERBB2-positive breast cancer but may have a
potential role in patients at risk for CNSmetastatic events and
has more side effects (particularly diarrhea). To investigate
further the efficacy of neratinib in metastatic ERBB2-positive
breast cancer, the National Surgical Adjuvant Breast and
Bowel Project (NSABP) Foundation has recently initiated a
phase 1b/2 study of neratinib in combination with ado-
trastuzumabemtansineassecond-linetherapy(NCT02236000).
We acknowledge the limitations of this study, including
changes to the study protocol, themost notable ofwhichwas
a reduction inaccrual goal from1200 to480patients for afore-
mentioned reasons. As such, the NEfERT-T study gives a
preliminary, rather than definitive, understanding of the ef-
ficacy and safety of neratinib-paclitaxel in the first-line treat-
ment of ERBB2-positive metastatic breast cancer. Further-
more, because patientswith progressive or symptomatic CNS
diseasewereexcluded fromthis study, it is notpossible topro-
vide any estimate of efficacy in this subgroup.
Conclusions
Neratinib in combination with paclitaxel was not superior in
termsofPFScomparedwith trastuzumab-paclitaxel in the first-
line treatmentofwomenwithERBB2-positivemetastaticbreast
cancer but showed similar efficacy and may delay the onset
and reduce the frequency of CNS metastases. Diarrhea was
more common with neratinib-paclitaxel; this drug regimen
requires aggressive primary prophylaxis of this adverse ef-
fect for the first cycle of therapy.
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